{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T15:44:20Z","timestamp":1763480660994,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction\/objectives<\/jats:title>\n                <jats:p>The ASCORE study on treatment for rheumatoid arthritis (RA) showed better retention and clinical response rates for abatacept as first-line versus later-line therapy. This post hoc analysis of ASCORE assessed 2-year retention, efficacy, and safety of subcutaneous (SC) abatacept in Germany, Austria, and Switzerland.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Adults with RA who initiated SC abatacept 125\u00a0mg once weekly were assessed. Primary endpoint was abatacept retention rate at 2\u00a0years. Secondary endpoints: proportions of patients with low disease activity (LDA)\/remission per Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (\u2264\u20093.2), Simplified Disease Activity Index (\u2264\u200911), and Clinical Disease Activity Index (\u2264\u200910). Outcomes were analyzed by treatment line and serostatus.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>For the pooled cohort, the 2-year abatacept retention rate was 47.6%; retention was highest in biologic-na\u00efve patients (50.5% [95% confidence interval 44.9, 55.9]). Patients seropositive for both anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF;\u2009+\u2009\/\u2009+) at baseline had a higher 2-year abatacept retention rate than patients with single seropositivity for either APCA or RF or double-seronegativity (\u2212\u2009\/\u2009\u2212), irrespective of treatment line. At 2\u00a0years, a higher proportion of patients who were biologic-na\u00efve were in LDA\/remission than patients with one or\u2009\u2265\u2009two prior biologics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A higher proportion of patients with\u2009+\u2009\/\u2009+\u2009RA (compared with\u2009\u2212\u2009\/\u2009\u2212\u2009RA) had abatacept retention after 2\u00a0years. Early identification of patients with seropositive RA may facilitate a precision-medicine approach to RA treatment, leading to a higher proportion of patients in LDA\/remission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration number<\/jats:title>\n                <jats:p> NCT02090556; date registered: March 18, 2014 (retrospectively registered).\n<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td colspan=\"3\"><jats:bold>Key Points<\/jats:bold><jats:italic>\u2022 This post hoc analysis of a German-speaking subset of European patients with RA from the global ASCORE study (NCT02090556) showed that retention of SC abatacept within this subset was 47.6%, with good clinical outcomes after 2 years.<\/jats:italic><jats:italic>\u2022 Patients with double-seropositive RA (ACPA and RF positive) had higher retention of abatacept than patients with double-seronegative RA (ACPA and RF negative). Retention and clinical responses were highest for patients who were biologic-na\u00efve compared with patients who had one or \u2265 two prior biologic treatments.<\/jats:italic><jats:italic>\u2022 These real-world data may be useful for clinicians in informing individualized treatment pathways for patients with RA, and fostering superior disease control and clinical outcomes.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-023-06649-x","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T06:02:07Z","timestamp":1686722527000},"page":"2321-2334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3395-4412","authenticated-orcid":false,"given":"Rieke","family":"Alten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Tony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Bannert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"N\u00fc\u00dflein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean E.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Chartier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karissa","family":"Lozenski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Hackl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Forster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Peichl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"6649_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"J Smolen","year":"2016","unstructured":"Smolen J, Aletaha D, McInnes I (2016) Rheumatoid arthritis. Lancet 388:2023\u20132038","journal-title":"Lancet"},{"key":"6649_CR2","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s00296-015-3271-8","volume":"35","author":"W Katchamart","year":"2015","unstructured":"Katchamart W, Koolvisoot A, Aromdee E, Chiowchanwesawakit P, Muengchan C (2015) Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis. Rheumatol Int 35:1693\u20131699. https:\/\/doi.org\/10.1007\/s00296-015-3271-8","journal-title":"Rheumatol Int"},{"key":"6649_CR3","doi-asserted-by":"publisher","first-page":"R949","DOI":"10.1186\/ar1767","volume":"7","author":"AHM van der Helm-van Mil","year":"2005","unstructured":"van der Helm-van Mil AHM, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7:R949-958. https:\/\/doi.org\/10.1186\/ar1767","journal-title":"Arthritis Res Ther"},{"key":"6649_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/acr.24071","volume":"72","author":"E Alemao","year":"2020","unstructured":"Alemao E, Bao Y, Weinblatt ME, Shadick N (2020) Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study. Arthritis Care Res (Hoboken) 72:176\u2013183. https:\/\/doi.org\/10.1002\/acr.24071","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6649_CR5","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581","journal-title":"Arthritis Rheum"},{"key":"6649_CR6","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millan I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA (2021) 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 73:1108\u20131123. https:\/\/doi.org\/10.1002\/art.41752","journal-title":"Arthritis Rheumatol"},{"key":"6649_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Muller-Ladner U, Mysler EF, da Silva JAP, Poor G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"6649_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nri.2016.124","volume":"17","author":"V Malmstrom","year":"2017","unstructured":"Malmstrom V, Catrina AI, Klareskog L (2017) The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol 17:60\u201375. https:\/\/doi.org\/10.1038\/nri.2016.124","journal-title":"Nat Rev Immunol"},{"key":"6649_CR9","unstructured":"Bristol Myers Squibb (2020) Orencia (abatacept) prescribing information.\u00a0https:\/\/packageinserts.bms.com\/pi\/pi_orencia.pdf. Accessed 09\/02\/2021"},{"key":"6649_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/ard.2007.074773","volume":"67","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le BM, Dougados M (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67:547\u2013554","journal-title":"Ann Rheum Dis"},{"key":"6649_CR11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3899\/jrheum.130263","volume":"41","author":"JM Kremer","year":"2014","unstructured":"Kremer JM, Peterfy C, Russell AS, Emery P, Abud-Mendoza C, Sibilia J, Becker J-C, Westhovens R, Genant HK (2014) Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial. J Rheumatol 41:1077\u20131087","journal-title":"J Rheumatol"},{"key":"6649_CR12","first-page":"553","volume":"32","author":"R Westhovens","year":"2014","unstructured":"Westhovens R, Kremer J, Emery P, Russell A, Alten R, Barre E, Dougados M (2014) Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Clin Exp Rheumatol 32:553\u2013562","journal-title":"Clin Exp Rheumatol"},{"key":"6649_CR13","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3899\/jrheum.170344","volume":"45","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente RM, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Elegbe A, Wong R, Li X, Banerjee S, Alten R (2018) Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. J Rheumatol 45:1085\u20131092. https:\/\/doi.org\/10.3899\/jrheum.170344","journal-title":"J Rheumatol"},{"key":"6649_CR14","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1002\/art.30463","volume":"63","author":"MC Genovese","year":"2011","unstructured":"Genovese MC, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Porawska W, Box J, Legerton C III, Nasonov E, Durez P, Aranda R, Pappu R, Delaet I, Teng J, Alten R (2011) Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheumatol 63:2854\u20132864","journal-title":"Arthritis Rheumatol"},{"key":"6649_CR15","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s10067-017-3587-8","volume":"36","author":"M Desplats","year":"2017","unstructured":"Desplats M, Pascart T, Jelin G, Norberciak L, Philippe P, Houvenagel E, Goeb V, Flipo RM (2017) Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. Clin Rheumatol 36:1395\u20131400. https:\/\/doi.org\/10.1007\/s10067-017-3587-8","journal-title":"Clin Rheumatol"},{"key":"6649_CR16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s10067-019-04449-w","volume":"38","author":"R Alten","year":"2019","unstructured":"Alten R, Mariette X, Lorenz HM, Nusslein H, Galeazzi M, Navarro F, Chartier M, Heitzmann J, Poncet C, Rauch C, Le Bars M (2019) Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study. Clin Rheumatol 38:1413\u20131424. https:\/\/doi.org\/10.1007\/s10067-019-04449-w","journal-title":"Clin Rheumatol"},{"key":"6649_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06176-1","author":"R Alten","year":"2022","unstructured":"Alten R, Mariette X, Flipo RM, Caporali R, Buch MH, Patel Y, Marsal S, Sanmarti R, Nurmohamed MT, Griffiths H, Peichl P, Bannert B, Chartier M, Connolly SE, Lozenski K, Rauch C (2022) Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-022-06176-1","journal-title":"Clin Rheumatol"},{"issue":"Suppl 2","key":"6649_CR18","first-page":"1639","volume":"78","author":"R Alten","year":"2019","unstructured":"Alten R, Mariette X, Buch M, Caporali R, Flipo R-M, Forster A, Nurmohamed M, Patel Y, Peichl P, Sanmarti R, Chartier M, Heitzmann J, Rauch C, Connolly S (2019) ASCORE, a 2-year, observational, prospective multicentre study of subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice: 1-year interim analysis. Ann Rheum Dis 78(Suppl 2):1639 (Abstract AB0361)","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"6649_CR19","first-page":"1392","volume":"77","author":"R Alten","year":"2018","unstructured":"Alten R, Mariette X, Buch M, Caporali R, Flipo R-M, Forster A, Nurmohamed M, Patel Y, Peichl P, Sanmarti R, Chartier M, Heitzmann J, Rauch C, Connolly SE (2018) Experience with subcutaneous abatacept in routine clinical practice: 6-month interim analysis of a 2-year, prospective, non-interventional, multicentre study in patients with RA. Ann Rheum Dis 77(Suppl 2):1392 (Abstract AB0461)","journal-title":"Ann Rheum Dis"},{"key":"6649_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, Aletaha D, Allaart CF, Bathon J, Bombardieri S, Brooks P, Brown A, Matucci-Cerinic M, Choi H, Combe B, de Wit M, Dougados M, Emery P, Furst D, Gomez-Reino J, Hawker G, Keystone E, Khanna D, Kirwan J, Kvien TK, Landewe R, Listing J, Michaud K, Martin-Mola E, Montie P, Pincus T, Richards P, Siegel JN, Simon LS, Sokka T, Strand V, Tugwell P, Tyndall A, van der Heijde D, Verstappen S, White B, Wolfe F, Zink A, Boers M (2011) American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 70:404\u2013413","journal-title":"Ann Rheum Dis"},{"key":"6649_CR21","doi-asserted-by":"publisher","first-page":"l67","DOI":"10.1136\/bmj.l67","volume":"364","author":"JE Gottenberg","year":"2019","unstructured":"Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X, French Society of R, the investigators participating in Air ORA, registries R (2019) Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ 364:l67. https:\/\/doi.org\/10.1136\/bmj.l67","journal-title":"BMJ"},{"key":"6649_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1620\/tjem.250.153","volume":"250","author":"S Okazaki","year":"2020","unstructured":"Okazaki S, Watanabe R, Harigae H, Fujii H (2020) Better Retention of Abatacept Is Associated with High Rheumatoid Factor: A Five-Year Follow-Up Study of Patients with Rheumatoid Arthritis. Tohoku J Exp Med 250:153\u2013159. https:\/\/doi.org\/10.1620\/tjem.250.153","journal-title":"Tohoku J Exp Med"},{"key":"6649_CR23","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jbspin.2019.07.006","volume":"86","author":"X Mariette","year":"2019","unstructured":"Mariette X, Schaeverbeke T, Gaudin P, Chartier M, Heitzmann J, Vannier-Moreau V, Hilliquin P, Cantagrel A (2019) Two-year abatacept retention rate in clinical practice in the French ACTION cohort. Joint Bone Spine 86:753\u2013759. https:\/\/doi.org\/10.1016\/j.jbspin.2019.07.006","journal-title":"Joint Bone Spine"},{"key":"6649_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s10354-019-00710-8","volume":"170","author":"P Peichl","year":"2020","unstructured":"Peichl P, Alten R, Galeazzi M, Lorenz HM, Nusslein H, Navarro F, Elbez Y, Chartier M, Hackl R, Rauch C, Connolly SE (2020) Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study. Wien Med Wochenschr 170:132\u2013140. https:\/\/doi.org\/10.1007\/s10354-019-00710-8","journal-title":"Wien Med Wochenschr"},{"key":"6649_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41927-020-00173-0","volume":"5","author":"E Choy","year":"2021","unstructured":"Choy E, Groves L, Sugrue D, Hurst M, Houghton J, Venkatachalam S, Patel YI, Maxwell JR, Pollock KG, Henning S (2021) Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study. BMC Rheumatol 5:3. https:\/\/doi.org\/10.1186\/s41927-020-00173-0","journal-title":"BMC Rheumatol"},{"key":"6649_CR26","doi-asserted-by":"publisher","first-page":"e000538","DOI":"10.1136\/rmdopen-2017-000538","volume":"3","author":"R Alten","year":"2017","unstructured":"Alten R, Mariette X, Lorenz HM, Galeazzi M, Cantagrel A, Nusslein HG, Chartier M, Elbez Y, Rauch C, Le Bars M (2017) Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study. RMD Open 3:e000538. https:\/\/doi.org\/10.1136\/rmdopen-2017-000538","journal-title":"RMD Open"},{"key":"6649_CR27","first-page":"489","volume":"34","author":"HG N\u00fc\u00dflein","year":"2016","unstructured":"N\u00fc\u00dflein HG, Alten R, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Peichl P, Pavelka K, Chartier M, Poncet C, Rauch C, Le BM (2016) Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study. Clin Exp Rheumatol 34:489\u2013499","journal-title":"Clin Exp Rheumatol"},{"key":"6649_CR28","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/art.39595","volume":"68","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhao H, Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh A (2016) Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the Pan-European registry analysis. Arthritis Rheumatol 68:1346\u20131352. https:\/\/doi.org\/10.1002\/art.39595","journal-title":"Arthritis Rheumatol"},{"key":"6649_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13075-020-2138-x","volume":"22","author":"P-C Liu","year":"2020","unstructured":"Liu P-C, Ssu C-T, Tsao Y-P, Liou T-L, Tsai C-Y, Chou C-T, Chen M-H, Leu C-M (2020) Cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells. Arthritis Res Ther 22:64. https:\/\/doi.org\/10.1186\/s13075-020-2138-x","journal-title":"Arthritis Res Ther"},{"key":"6649_CR30","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1007\/s10067-019-04648-5","volume":"38","author":"R Alten","year":"2019","unstructured":"Alten R, Feist E, Lorenz HM, Nusslein H, Voll RE, Chartier M, Elbez Y, Rauch C (2019) Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries. Clin Rheumatol 38:3049\u20133059. https:\/\/doi.org\/10.1007\/s10067-019-04648-5","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06649-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06649-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06649-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T11:13:15Z","timestamp":1691579595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06649-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["6649"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06649-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2023,6,14]]},"assertion":[{"value":"27 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments, the International Conference on Harmonization Good Clinical Practice Guidelines, and the International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Epidemiology Practices. The laws and regulatory requirements of all countries participating in this study were adhered to. The study protocol and patient enrollment materials were approved according to local law in each participating country prior to initiation of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants signed an informed consent form prior to their participation in the study and agreed to have their data published for research purposes, given that the data provided were first anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"RA has received consulting fees from AbbVie, Bristol Myers Squibb, Celltrion, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and Roche; and has received grant\/research support from Bristol Myers Squibb, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and Roche. BB, PP, AF, and HN declare no competing interests. CR (at time of analysis), MC, SEC, RH, and KL are employees of and shareholders in Bristol Myers Squibb. H-PT has received consulting fees from AbbVie, Bristol Myers Squibb, Chugai, Galapagos, Gilead, Janssen, Lilly, Novartis, and Roche.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}